Use of subcontractors a strain on GCP compliance, EMA says

By Nick Taylor

- Last updated on GMT

Related tags: Ema, Clinical trial, European medicines agency

Use of subcontractors a strain on GCP compliance, EMA says
The EMA has warned sponsors must take “great care” when outsourcing to niche subcontractors to avoid violating GCP.

Use of niche subcontractors for tasks such as data management and IVRS (interactive voice response services) broadens the number of parties involved in a clinical trial. The European Medicines Agency (EMA) has expressed concerns about the model’s impact on good clinical practice (GCP) compliance.

This fragmented distribution of tasks could put additional strain on the maintenance of quality assurance and compliance and obscure the clear responsibility and reporting lines for these tasks​”, the EMA said in its GCP question and answer document​.

Sponsors working with a network of subcontractors must take “great care​” to ensure distribution of tasks is documented and agreed, EMA said, and “properly​” inform ethics committees of the activities.

Responsibility lies with the sponsor or investigator but the EMA wants the distribution of all tasks to be documented in the protocol, procedures, or contracts. The US Food and Drug Administration (FDA) has a similar stance on transferring responsibility​ to contract research organisations (CROs).

Sponsors should also consider the specifics of each particular clinical trial from the planning phase onwards. “This is important where entering into novel arrangements that may arise, for instance in the case of SMOs (site management organisations)​”, the EMA said.

SMOs are highlighted by the EMA because they perform roles linked to the “responsibilities of the investigator​” but have their “contract and funding with the sponsor​”. Tasks handled by SMOs may also put them in contact with study subjects.

Patient contact

Sponsors must pay particular attention when subcontractors have direct contact with patients. Personal details must only be shared with parties that have ethics committee approval, the EMA said, and as such use of subcontractors in these roles must be considered in advance.

The EMA published the text in response to the following question: “GCP sets out responsibilities for the sponsor and the investigator, but tasks are increasingly undertaken by a range of contractors – how should this situation be addressed?​”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars